Laronde

Laronde is a biopharmaceutical company that specializes in developing eRNA-based therapeutics designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative platform, known as Endless RNA, is characterized by its persistence, non-immunogenic properties, and adaptability for repeat dosing and various delivery methods. This flexibility positions Laronde to support the simultaneous advancement of multiple therapeutic programs across different disease areas, aiming to create more predictable and impactful medicines for patients. The company's approach seeks to redefine the possibilities of therapeutic development, ultimately contributing to the creation of essential medicines for the future.